Kolexia
Deleuze Antoine Oncologie médicale
Deleuze Antoine
Oncologie médicale
Centre Eugène Marquis
Rennes, France
60 Activités
176 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Tumeurs du sein Tumeurs du sein triple-négatives Tumeurs de l'utérus Néphrocarcinome Maladie trophoblastique gestationnelle Tumeurs de la prostate Tumeurs de l'endomètre Choriocarcinome

Collaborateurs

Voir plus
Baty Manon
Baty Manon
Centre Eugène Marquis, Rennes, France
Crouzet Laurence
Crouzet Laurence
Centre Eugène Marquis, Rennes, France
Robert Lucie
Robert Lucie
Centre Eugène Marquis, Rennes, France
Laguerre Brigitte
Laguerre Brigitte
Centre Eugène Marquis, Rennes, France

Industries

Voir plus
Novartis
4 collaboration(s)
Dernière en 2023
Daiichi Sankyo
3 collaboration(s)
Dernière en 2023
Edimark
2 collaboration(s)
Dernière en 2023
Lilly
1 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
ECLECTIC: EstroTEP and Circulating Biomarkers to Determine the Optimal Second Line Therapy for ER-positive HER2-negative Metastatic Breast Cancer Patients
Essai Clinique (Zionexa)   08 janvier 2024
Cancers gynécologiques
Edimark   21 décembre 2023
797P Impact of consolidation cycles in predicting recurrence in patients treated with EMA-CO for high-risk gestational trophoblastic neoplasia
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Management of trophoblastic tumors : review of evidence, current practice, and future directions.
Expert review of anticancer therapy   22 mai 2023
237P Real-world safety and efficacy of trastuzumab-deruxtecan (T-DXd) in HER2-positive advanced breast cancer (ABC) elderly patients (pts): The TREX-Old retrospective registry
Abstract Book of ESMO Breast Cancer 2023, Berlin, Germany, 11-13 May 2023   01 mai 2023
Urachal carcinoma: a large retrospective multicentric study from the French Genito-Urinary Tumor Group.
Frontiers in oncology   19 janvier 2023
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group.
ESMO open   21 décembre 2022
New drug approval: Pembrolizumab - Neoadjuvant/adjuvant treatment for localized high-risk triple negative breast cancer.
Bulletin du cancer   22 juillet 2022
177P Low HER2 expression does not influence prognosis in metastatic triple-negative breast cancer: Results from an international, multicenter analysis coordinated by the Austrian Group Medical Tumor Therapy (AGMT)
Abstract Book of ESMO Breast Cancer 2022, Berlin, Germany, 03-05 May 2022   01 mai 2022
Paraneoplastic cerebellar degeneration associated with anti-Yo antibodies in uterine papillary serous carcinoma.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society   07 février 2022